AbbVie Inc. v. Watson Laboratories Inc. - Florida
1:12-cv-01409
Overview
Parties
Defendant
Watson Laboratories Inc. - Florida Operating Company
Represented By
2 Attorneys ListedFriedlander & Gorris, P.A.
Friedlander & Gorris, P.A., 1201 N. Market Street
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
AbbVie Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Abbott Respiratory LLC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Counter Claimant
Watson Pharma Inc. Operating Company
Represented By
1 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Watson Pharmaceuticals Inc. Operating Company
Represented By
1 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 25 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 6,080,428 A Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,129,930 A | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,676,967 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,818,229 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,406,715 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 6,746,691 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,011,848 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,998,506 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2006026342 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2007022534 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2007022427 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2007023781 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2007023266 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2008004557 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2009003650 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6080428
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
Filed: 1995-01-14
Issued: 2000-06-27
|
Expired (Term Ended)
Expires: 2015-01-14
|
|
|
US6469035
Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
|
Filed: 1997-07-31
Issued: 2002-10-22
|
Expired (Term Ended)
+227d PTA
Expires: 2018-03-15
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).